Therapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs.

Hdl Handle:
http://hdl.handle.net/10147/132293
Title:
Therapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs.
Authors:
Costello, R W; Long, D A; Gaine, S; Mc Donnell, T; Gilmartin, J J; Lane, S J
Affiliation:
Departments of Respiratory, Medicine Beaumont Hospital, Dublin, 9, Ireland, rcostello@rcsi.ie.
Citation:
Therapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs. 2011:notIr J Med Sci
Journal:
Irish journal of medical science
Issue Date:
11-May-2011
URI:
http://hdl.handle.net/10147/132293
DOI:
10.1007/s11845-011-0716-2
PubMed ID:
21557095
Additional Links:
http://www.ncbi.nlm.nih.gov/pubmed/21557095
Abstract:
BACKGROUND: Patients with asthma who have persistent symptoms despite treatment with inhaled steroids and long-acting beta agonists are considered to have severe asthma. Omalizumab is a monoclonal antibody directed against IgE, which is used as an add-on treatment for patients who have severe persistent allergic asthma. AIMS: The aim of this study was to assess the clinical benefit and healthcare utilisation of patients who responded to omalizumab therapy and to establish an overall cost implication. METHODS: This was an observational retrospective cohort study designed to investigate the effect of omalizumab on exacerbations of asthma before and after 6 months of treatment in Irish patients. RESULTS: Centres who had treated patients with severe allergic asthma for the 6 months prior and post omalizumab treatment were audited with a standardised assessment tool. Sixty-three (32 male) patients were studied. In the 6 months prior to omalizumab 41 of 63 (66%) had been hospitalised, and this fell to 15 of 63 (24%), p < 0.0001 in the 6 months after treatment was started. Hospital admissions reduced from 2.4 ± 0.41 to 0.8 ± 0.37 and the mean number of bed days occupied was reduced from 16.6 ± 2.94 to 5.3 ± 2.57 days, p < 0.001. The number of oral corticosteroid doses used fell from 3.1 ± 0.27 to 1.2 ± 0.17, p < 0.001. The overall cost saving per omalizumab responder patients for 6 months was <euro>834. CONCLUSIONS: Six months therapy with omalizumab reduced the number of bed days, the number of hospitalisations and the use of oral corticosteroids compared to the 6 months prior to commencement. Despite the cost of the additional therapy there were overall savings in health costs.
Item Type:
Article
Language:
en
ISSN:
1863-4362

Full metadata record

DC FieldValue Language
dc.contributor.authorCostello, R Wen
dc.contributor.authorLong, D Aen
dc.contributor.authorGaine, Sen
dc.contributor.authorMc Donnell, Ten
dc.contributor.authorGilmartin, J Jen
dc.contributor.authorLane, S Jen
dc.date.accessioned2011-05-27T15:28:01Z-
dc.date.available2011-05-27T15:28:01Z-
dc.date.issued2011-05-11-
dc.identifier.citationTherapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs. 2011:notIr J Med Scien
dc.identifier.issn1863-4362-
dc.identifier.pmid21557095-
dc.identifier.doi10.1007/s11845-011-0716-2-
dc.identifier.urihttp://hdl.handle.net/10147/132293-
dc.description.abstractBACKGROUND: Patients with asthma who have persistent symptoms despite treatment with inhaled steroids and long-acting beta agonists are considered to have severe asthma. Omalizumab is a monoclonal antibody directed against IgE, which is used as an add-on treatment for patients who have severe persistent allergic asthma. AIMS: The aim of this study was to assess the clinical benefit and healthcare utilisation of patients who responded to omalizumab therapy and to establish an overall cost implication. METHODS: This was an observational retrospective cohort study designed to investigate the effect of omalizumab on exacerbations of asthma before and after 6 months of treatment in Irish patients. RESULTS: Centres who had treated patients with severe allergic asthma for the 6 months prior and post omalizumab treatment were audited with a standardised assessment tool. Sixty-three (32 male) patients were studied. In the 6 months prior to omalizumab 41 of 63 (66%) had been hospitalised, and this fell to 15 of 63 (24%), p < 0.0001 in the 6 months after treatment was started. Hospital admissions reduced from 2.4 ± 0.41 to 0.8 ± 0.37 and the mean number of bed days occupied was reduced from 16.6 ± 2.94 to 5.3 ± 2.57 days, p < 0.001. The number of oral corticosteroid doses used fell from 3.1 ± 0.27 to 1.2 ± 0.17, p < 0.001. The overall cost saving per omalizumab responder patients for 6 months was <euro>834. CONCLUSIONS: Six months therapy with omalizumab reduced the number of bed days, the number of hospitalisations and the use of oral corticosteroids compared to the 6 months prior to commencement. Despite the cost of the additional therapy there were overall savings in health costs.-
dc.languageENG-
dc.language.isoenen
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/21557095en
dc.titleTherapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs.en
dc.typeArticleen
dc.contributor.departmentDepartments of Respiratory, Medicine Beaumont Hospital, Dublin, 9, Ireland, rcostello@rcsi.ie.en
dc.identifier.journalIrish journal of medical scienceen
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.